Biobank Norway coordinates Norwegian biobanks with the health industry to ensure that the valuable biosamples are used to develop new, breakthrough treatments.

How will biobanks accelerate cancer research?

Biobanks ­– the powerful tools in cancer research you may have never heard of.

 

Biobank Norway is a national research infrastructure that comprises all public biobanks in Norway and represents one of the world’s largest existing resources within biobanking. They are also a member of Oslo Cancer Cluster, through NTNU, and represent an exciting initiative in the endeavour to develop precision medicine.

 

A biobank is a storage facility that keeps biological samples to be used for medical research. The samples come from population-based or clinical studies.

 

Christian Jonasson, seniorforsker ved NTNU.

Christian Jonasson, seniorforsker ved NTNU.

Christian Jonasson, the Industry Coordinator for Biobank Norway, connects businesses with Norwegian biobanks to accelerate medical research. He said that more biobanks now work with the health industry and benefit from added value in the process.

“It is the health industry that will ultimately bring new therapies to patients.”
Christian Jonasson

Biobank Norway has developed several strategic areas for Norwegian biobanks. They have built automated freezers for secure long-term storage, with advanced robotised systems that can retrieve barcoded biological samples. They have initiated new biobanks, established new IT systems and also developed policies for public-private collaborations. Also, they have contributed to strategic processes that promote increased utilization of Norwegian health data, including the national Health Data Program.

Ultimately, Biobank Norway aims to facilitate collaborations between the global health industry and Norwegian biobanks to accelerate innovation in the life sciences, disease prevention and treatment.

“Biobanks are one of the most important tools in precision medicine.” Christian Jonasson

 

Biosamples may be used for important, life-saving cancer research. For example, to develop new immunotherapies, such as T cell therapy. Photograph by Christopher Olssøn

 

A competitive edge

Norway has been collecting biological samples for the last 30-40 years. For example, one of the world’s largest birth cohort studies, the Mother and Child study (called MoBa) was initiated in 1999. It included 100 000 newborns with mother and father, which totalled over 285 000 participants over a ten-year period. There are numerous other Norwegian health studies, which have involved hundreds of thousands of people, such as the HUNT study and the Tromsø study.

Moreover, the Norwegian Radium Hospital have collected countless valuable samples from cancer patients over the years from both regular clinical care and from clinical research studies. Hospitals across Norway also continually collect and save diagnostic samples, which may be used for medical research at a later stage.

The number of biobanks and the rigorous collection of clinical data in health registers in Norway represent unique assets for medical researchers.

“Norway has a competitive edge on its health data infrastructure.” Christian Jonasson

 

Sharing the data

However, Jonasson also points out that the health registers in Norway are too fragmented. To combat the problem, Biobank Norway are helping the Norwegian Directorate of eHealth to develop a Health Data Program. The digital platform, called the Health Analytics Platform (HAP), will collate copies of relevant data from the various health registers, providing a single point of easy access for researchers.

Biobank Norway also has a long-term vision to collect all biobank data and health data in a common platform. This is a necessary step to unleash a larger national precision medicine initiative. First, they want to organise the data from the four largest population-based cohort studies in one place. In a couple of years, this database would hopefully include 400 000 people, which is a very attractive cohort for medical research.

“We need to attract leading actors from the international health industry and Norwegian start-ups in real collaborations with biobanks.” Christian Jonasson

Important medical research is already being conducted in biobanks across Norway. Jonasson said that there now needs to be a plan to market Norwegian health data and biobanks internationally to spur innovation further.

 

Biosamples are also used for sequencing of the human genome, to develop more precise diagnosis and treatment of cancer.

 

The hidden key

To unlock the potential of biobanks, the biological samples need to be analysed and converted into meaningful data, which can be an expensive and laborious process.

Finland, for example, has begun to collect biological samples from 500 000 individuals. One single database holds all phenotypic data, such as diagnosis and treatment, and all genotypic data, which is the mapping of the human genome.

In the UK, there is the Genomics Project, which has already sequenced the DNA (the coded parts of the human genome) of 100 000 patients. The UK Biobank are aiming to sequence the DNA of half a million brits.

Jonasson hopes that such ambitious initiatives will be imported to Norway to build the biobank infrastructure further and provide meaningful data for medical research. He adds that public-private collaborations will be key to drive and fund such large scale initiatives.

Biobank Norway is currently in the process of extending into its third phase and aims to continue to improve the biobanks, the partner institutions and global research collaborations in the future.

 

  • Do you need help with your research and innovation project using biobanks in Norway?
    E-mail Christian Jonasson.
  • For more information, please visit the official website of BioBank Norway.

 

Sign up to OCC newsletter

Kronikk: Dine helsedata kan styrke helsenæringen

This opinion piece was first published on 9 May 2019 in Dagens Medisin, by Ketil Widerberg, General Manager at Oslo Cancer Cluster, and Christian Jonasson, Senior Adviser at NTNU. Both are also members of a work group for innovation and business development for the Health Data Program for the the Norwegian Directorate of eHealth. Please scroll to the end of this page for an English summary.

 

Vi får nye forretningsmodeller innen helse som er basert på digitalisering og persontilpasset medisin. Her kan Norge virkelig lede an!

Christian Jonasson, seniorforsker ved NTNU.

Christian Jonasson, seniorforsker ved NTNU.

Ketil Widerberg, daglig leder i Oslo Cancer Cluster.

HELSE BLIR digitalisert og medisin blir tilpasset den enkelte pasienten. Dette er to megatrender som vil endre forretningsmodellen for helseindustrien. Forrige uke kom Stortingsmeldingen om nettopp helsenæringen. Den åpner for store muligheter for Norge.

I bilindustrien erstatter gradvis digital mobilitet den tradisjonelle boksen på fire hjul. Et eksempel er at Tesla blir verdsatt høyere enn tradisjonelle bilprodusenter blant annet for sin evne til kontinuerlig datainnsamling fra bilene. I helsenæringen vil vi se det samme.

 

NYE MODELLER. Med digital persontilpasset medisin vil nye forretningsmodeller vokse frem. Vi ser eksemplene daglig: Roche, et globalt legemiddelselskap, har nylig kjøpt opp helsedataselskapet Flatiron. Oppkjøpet gjorde de for å kunne utvikle nye kreftbehandlinger raskere, for nettopp tid er viktig for kreftpasienter som kjemper mot klokka. Et annet legemiddelselskap, AstraZeneca, har ansatt toppleder fra NASA. Norske DNVGL, som tradisjonelt har jobbet med olje, gass og shipping, har nå helsedata som et satsingsområde.

Helsemyndigheter erkjenner også endringen mot mer datainnsamling. Legemidler blir mer målrettede og brukes på stadig mindre undergrupper av pasienter. Dette utfordrer hva som er nødvendig kunnskapsgrunnlag for å gi pasienter tilgang til ny behandling. Mens det i dag er kunnskap om gjennomsnitt for store pasientgrupper som ligger til grunn for beslutninger om nye behandlingsmetoder, er det med persontilpasset behandling nettopp viktig å ta mer hensyn til individer og små undergrupper. De amerikanske helsemyndighetene (FDA) har derfor lagt frem retningslinjer for hvordan helsedata kan brukes som beslutningsgrunnlag for nye legemidler.

 

NORSKE FORTRINN. Legemiddelverket i Norge gir uttrykk for at de også ønsker å være i front i denne utviklingen – for også de ser at helsedata gir bedre beslutningsgrunnlag.

Hvordan kan så Norge lede an? Norge har konkurransefortrinn knyttet til et sterkt offentlig helsevesen, landsdekkende person- og helseregister og biobanker som kan knyttes sammen gjennom våre unike fødselsnummer. Dette er få land forunt! Derfor kan vi utnytte dette konkurransefortrinnet for å ta en posisjon i den store omveltningen av helsesektoren og helsenæringen.

Nedenfor følger noen forslag som vi mener vil styrke Norges stilling.

 

PLATTFORM. Vi kan starte med å lage en norsk dataplattform. Selskap leter globalt etter helsedata av god kvalitet. La oss utvikle en dataplattform hvor helsedata er raskt og sikkert tilgjengelig for norske og utenlandske aktører. Et eksempel er helseanalyseplattformen. Her må data gjøres tilgjengelig for alle aktører og for alle legitime formål. Samarbeidsmodeller må utvikles som sikrer at verdiskapingen blir i Norge og pasientene får bedre behandling.

Vi kan utvikle bedre økosystemer. Verdiskapingspotensialet for helsedata ligger i skjæringspunktet mellom offentlig og privat. Dagens offentlige forvaltere av helsedata må derfor samarbeide tettere med norske oppstartsbedrifter og internasjonale aktører.

 

INNSYN. Vi kan bruke personvern som konkurransefortrinn. Hver og en av oss eier våre egne helsedata. Derfor er det viktig med digitale plattformer som gir oss innsyn i egne helsedata.

Hvordan vi kommer til å bruke helsedata om få år, er vanskelig å forutse, akkurat som det var vanskelig å forutse hva konsesjonsutlysningen for oljeutvinning i 1965 ville føre til. Historien viser imidlertid at slike avgjørelser kan ha stor betydning for fremtidens verdiskapning i Norge, og for pasienter i hele verden. La oss derfor ikke overlate til tilfeldighetene hva vi i Norge gjør med våre helsedata.

 

 

English summary:

Digitalisation and precision medicine are influencing emerging business models in the health industry. It is time for Norway to lead the way!

As precision medicine develops, data gathering becomes ever more important. Instead of relying on results from a big patient group, cancer researchers are using big data to find out how treatments can be customised for small patient groups and individual patients.

Norway has a competitive advantage on health data: thanks to its strong public health sector, national health registers and biobanks that can be connected to unique personal ID numbers.

We suggest creating a common platform for Norwegian data, where high quality data can be accessed securely by legitimate national and international companies. Through collaborative models, we can ensure that the medical breakthroughs stay in Norway and benefit the patients. We need to develop better ecosystems that inspire simple collaboration between international key players, Norwegian start ups and the public agencies that handle health data.

Data privacy can be used as an asset. If we ensure everyone has complete access and insight into their own personal health data, people can be empowered to share it for the common good.

The decisions we make today will have great ramifications for the future value creation in Norway and for cancer patients across the world. We should not leave it up to chance.

 

Sign up to OCC newsletter

Jeg vil gjerne legge lista høyt og foreslå en felles database for data fra kliniske studier, hvor både firmaer og myndigheter har tilgang til helsedata umiddelbart etter at hver pasient har fått sin behandling, skriver Ketil Widerberg.

Hvordan gjør vi våre mest intime data til gull?

The following opinion piece was written by Ketil Widerberg, General Manager at Oslo Cancer Cluster, and published in Aftenposten on 1 May 2019. It is a response to an opinion piece written by Nikolai Astrup, the Norwegian Minister of Digitalization, which was published on 22 April 2019. The texts are only available in Norwegian, but a short summary in English is available at the bottom of this page.

 

Helsedata er en voksende gullåre, men vi kan ikke grave i den uten videre.

 

I Aftenposten 17. april svarer digitaliseringsminister Nikolai Astrup (H) på en appell om våre verdifulle data.

Astrup påpeker at data ikke kan sammenlignes med olje, for det er ikke staten, men hver og en av oss, som eier våre egne personopplysninger.

Det gjelder i høyeste grad de mest intime av våre data: helsedata.

 

En gullåre av data

Helsedata er en voksende gullåre, men vi kan ikke grave i den uten videre.

Hadde vi ikke først bygd opp beskyttelse av norske data og kompetanse, ville ikke prosjekter som DoMore blitt til.

Forskerne i DoMore bruker avansert bildeanalyse for å gi mer presise kreftprognoser. Samtidig ville ikke prosjektet eksistert uten internasjonale data og kompetanse.

For næringen som jeg jobber i, helsenæringen, er spørsmålet hvordan vi skal unngå å falle i digitaliseringsfellen. Der har mediebransjen landet.

Facebook og Google får all verdens data gratis gjennom samtykke og tar dermed livsgrunnlaget fra tradisjonelle aktører.

 

Trenger god strategi for kunstig intelligens

For norsk helsenæring blir de to strategiene som digitaliseringsministeren snart lanserer, digitalisering i offentlig sektor og kunstig intelligens, svært viktige. I en strategi for offentlige data oppfordrer jeg derfor til at fremskritt innen presisjonsmedisin tas med.

Da Kreftregisteret ble etablert på 50-tallet, forsto ingen den fulle nytteverdien av et slikt register. I dag tiltrekkes forskere og bedrifter fra hele verden for å få bruke data derfra.

Det viser hvorfor vi også i dag bør samle inn mer helsedata enn vi kan dra nytte av umiddelbart.

Hvordan finner vi balansen mellom god bruk av helsedata for å skape næring og rå utnyttelse av store firmaer? Her trenger vi en god strategi også for kunstig intelligens, som tar inn over seg denne balansegangen i helsedata.

Kunstig intelligens gjør presisjonsmedisin mulig på et helt annet nivå enn vi er på i dag, med mye høyere presisjon i behandlingen.

 

Ressurs for pasienter

For fremtidens presisjonsbehandling er helsedata ressursen vi må samle på. Vi må samle inn helsedata som gjør behandlingen bedre for neste pasient. Og vi trenger en struktur av dataene der både firmaer og myndigheter har tilgang til dem.

Jeg vil gjerne legge lista høyt og foreslå en felles database for data fra kliniske studier, hvor både firmaer og myndigheter har tilgang til helsedata umiddelbart etter at hver pasient har fått sin behandling.

Dette kan bidra til raskere tilgang til ny behandling og bedre oppfølging av pasienter med sykdommer som kreft.

Data former kreftbehandling og skaper nye tilbud til pasienter. Hvordan sikrer vi verdien av dataene? Skal vi gi dem bort for å bygge forskning og industri, skal vi ta så mye penger som vi kan for dem, eller skal vi prøve å finne på noe midt imellom?

I arbeidet med de nye strategiene bør våre mest intime data bli diskutert – med sikte på å skape verdi og næring av dem.

 

 

Short summary in English:

The question Astrup raised in his opinion piece concerned how data sharing can be improved across the public sector in Norway.

Widerberg responds by highlighting how we can make use of our health data to create added value and a successful health industry, without allowing large multinational corporations exploit the data freely.

Artificial intelligence makes precision medicine possible on a much higher level than today. We need to collect health data in order to improve treatments for future patients.

Widerberg therefore proposes a database where health data from all clinical trials is made available to both private and public bodies. This would contribute to making better treatments available sooner and provide better follow-up to patients suffering from diseases, such as cancer.

 

Sign up to OCC newsletter

Oslo Cancer Cluster's General Manager Ketil Widerberg at the EHiN conference in 2018.

The e-health meeting place

Oslo Cancer Cluster will co-power the conference E-health in Norway (EHiN).

– This is a natural continuation of the work we do in digitalisation, for a better understanding of cancer and better patient treatment, said Ketil Widerberg, General Manager of Oslo Cancer Cluster, at EHiN 2018.

The Norwegian Ministry of Health and Care Services (HOD) and ICT Norway started a collaboration on creating a national meeting place for e-health. ICT Norway launched the first EHiN conference five years ago. Oslo Cancer Cluster is happy to announce that we are now one of the three stakeholders in this yearly conference, together with ICT Norway and Macsimum.

EHiN attracts a large audience from Norwegian government and business. The speaker in this picture is Christine Bergland, Director at the Norwegian Directorate of eHealth (NDE).

Norwegian e-health  
EHiN 2018 took place in Oslo Spektrum and was the biggest meeting place for actors in the public and private sector working with e-health in Norway. The conference had 150 speakers and 1300 participants. EHiN 2019 will be the 6th year of the conference.

What happened at EHiN 2018?

 — EHiN is an important meeting place for public and private actors, and for academia and business. This is a natural prolongation of the many meeting places Oslo Cancer Cluster is always working to establish and preserve, Ketil Widerberg says.

Digital technologies are part of what drives innovation to the maximum benefit of cancer patients. Widerberg is certain that e-health will change the way we understand and treat cancer in the future.

– E-health is part of the matrix for how we give the right medicine to the right patient at the right time, meaning precision medicine. One example of what we specifically do in this area, is a recent project we have been part of, called PERMIDES.

An e-health success story
From August 2016 until August 2018, Oslo Cancer Cluster together with five other European clusters in medicine and ICT, was managing a Horizon 2020 EU project called PERMIDES. It is a European e-health success story in bringing together biopharma and IT sectors.

D.B.R.K Gupta Udatha at the EHiN conference in 2018. Dr. Udatha was the project manager for PERMIDES at Oslo Cancer Cluster.

D.B.R.K Gupta Udatha is Director (Digital and EU) at Oslo Cancer Cluster. He has been instrumental in PERMIDES and explains why the project has had such a positive effect on the small and medium sized enterprises (SMEs) it has worked with. 

PERMIDES was a project to anchorage digital transformation across SMEs in biotechnology and pharmaceuticals. We aimed to see where the biopharma companies were lacking digital infrastructure and where the ICT companies could bring digital skills to make sure that the biopharma companies were up to date, Dr. Udatha said at EHiN 2018.

The project created matchmaking opportunities between these two different categories of companies and was awarded EUR 4.8 million from the EU’s Horizon2020 programme. It addressed specific challenges for SMEs to go digital with a precision medicine product.

Read more bout the PERMIDES project here.

Norway’s Prime Minister Erna Solberg hosted the latest Northern Future Forum 30 October 2018. During the forum, the Prime Ministers of the Nordic and the Baltic countries and the UK came together in Oslo Cancer Cluster Innovation Park to discuss health technologies and the role these crucial technologies can play in the health systems of the future. In this picture, the ministers get a guided tour of Oslo Cancer Cluster Incubator and the laboratories with Ketil Widerberg as their guide. Photo: Kilian Munch/Statsministerens kontor

Let us cooperate on precise health technologies

International cooperation is key to fulfilling our vision of making cancer treatments more precise, and giving the patients new treatments more quickly.

This opinion piece is written by Ketil Widerberg, General Manager at Oslo Cancer Cluster. It was first published in the Norwegian newspaper Today’s Medicine, Dagens Medisin, 30 October 2018. 

The countries in Northern Europe have contributed to developing medical treatments that we today could not imagine living without. From the British discovery of antibiotics to the Danish development of a treatment for diabetes. Once again it is time for Northern European health innovation, this time in the field of health technology. What might the prime ministers from Northern Europe focus on when they meet in Oslo on 30 October to discuss health technology?

They might want to point out concrete and state-of-the-art initiatives from their respective countries. It could be Swedish biobanks, Finnish artificial intelligence, Danish health data, English genomics and Estonian health blockchain. These are exciting initiatives that make medicine more precise. This is particularly important when it comes to cancer because more precise treatments could save lives and limit the late effects resulting from imprecise treatment.

This opinion piece is written by Ketil Widerberg, General Manager at Oslo Cancer Cluster. It was first published in the Norwegian newspaper Today’s Medicine, Dagens Medisin, 30 October 2018.

At the same time, we see the contours of serious challenges arising with more precise medicine, such as each unit becoming more expensive. Smaller patient groups also mean that it is harder to find enough patients to understand the biological processes and the consequences of new medical treatments. As the prime ministers gather in Oslo to discuss health technology and plan the road ahead, it would not be amiss for them to look back in time and find inspiration from another technological development.

Precise through cooperation
In the 1990s, the search engine Yahoo helped us to quality-assure by categorising and being precise when we needed information on the internet. Yahoo thus contributed to the internet changing the world. However, the amount of data soon became enormous and complex, and a never-ending need for resources and experts arose. The traditional categorisation to ensure quality and structure the data became an impossible task.

This is very similar to what is happening in the health field today. We are constantly collecting more data and educating an increasing number of experts. With a few exceptions, every country is now collecting their data in their own registers and using a great deal of resources on assuring the quality of the data. The countries are rightfully proud of their initiatives. In Norway, we are proud of our biobanks and our health registers, such as the Cancer Registry of Norway. At the same time, we need to ask ourselves whether this national strategy really is the smartest way forward.

Let us go back to Yahoo. Towards the end of the 1990s, some engineers in California thought differently about the internet. How about using cooperation as a quality indicator? Instead of categorising, the links between the websites could ensure data quality. This is how Google was born, and we got precision, quality and insight into data that changed the world.

There are different challenges in the health field than on the internet. Data are more sensitive and the consequences for individuals can often be more dire. At the same time, health technology, in many ways, has reached the same point as the internet faced in the 1990s.  We do not have the quantity, the methods for analysis, or the quality to fully exploit the data to gather insight, or for treatment or innovation – yet.

From Yahoo to Google level
One way in which we could tackle the health technology challenges the data present us with is through international cooperation. It is about two things: to gather enough data, and to analyse the data to provide better and more precise treatment. The initiatives so far are promising, but they lack the potential to make the leap from Yahoo to Google.

The Northern European prime ministers can probably acknowledge this. The question is: what can they do? Should they encourage smart young engineers to analyse health data instead of developing the next app? Or should they change the way the hospitals buy technology?

A step in the right direction could be to look at what works best in the other countries. At the same time, we need to avoid new initiatives merely becoming a better horse-drawn carriage. Are there initiatives in existence that are scalable internationally so that we can bring health data up to the next level together? The answer is yes, but it requires visionary initiatives that have not been done anywhere else.

Common clinical studies
An area that the prime ministers will be able to highlight is a Northern European initiative for clinical studies. Together, the countries have a large number of patients, which gives researchers and doctors a better basis in their studies to understand more and provide better treatment. Such an initiative could also use health data from the national health services collected on a daily basis in several countries, known as real world data, instead of eventual clinical studies with patients over several years. This would be both quicker and much cheaper.

The prime ministers might also agree on cooperating on Northern European genetics. For 13 years, we collaborated on mapping our genes in the international  Human Genome Project. Now we need to get together to understand genes and treat the patients. With prioritised funding, genetics will soon be a part of the everyday clinical life in England. We can learn a lot from their experience.

Artificial intelligence
Lastly, the Northern European prime ministers may wish to collaborate on artificial intelligence in the health field. Today, cancer treatment, for instance, often only works on three out of ten patients. Artificial intelligence will change how we understand diseases such as cancer and how we treat the patients. The experiences from Finland of introducing artificial intelligence will help other countries to understand where the barriers are and where help might be needed first.

Oslo Cancer Cluster’s vision is to make cancer treatment more precise and provide new treatments more quickly to the patients. We see that international cooperation is key to obtaining this goal. As a result, we could also discover diseases more quickly and reduce the costs of the national health services. We hope the Northern European prime ministers will delve into these issues when they meet to discuss the health technologies of the future here with us.

By Ketil Widerberg, General Manager at Oslo Cancer Cluster.

Ketil Widerberg, General Manager at Oslo Cancer Cluster, opened the meeting on intelligent and personalized algorithms to prevent cancer 20 September 2018.

American tech and Norwegian health data

Combining country scale population data with world class computer systems and algorithms will push the boundaries of precision medicine.

This is a story about the unique American-Norwegian collaboration that combines the best health data with the most powerful computers in a pioneer project run by Cancer Registry of Norway and Lawrence Livermore National Laboratory.

Data to screen cancer 
The ongoing project was initiated after a talk on tech between the General Manager of Oslo Cancer Cluster and a Senior Scientist from Lawrence Livermore National Laboratory. Some months later, in San Francisco, a meeting room was filled with some of the world’s best minds on cancer and technology. The Norwegians knew cancer and the Americans knew computing. The outcome was unknown. 

They identified a concrete challenge. Can we see patterns in data to screen cancer more precisely?

The quest resulted in a successful cooperation between Lawrence Livermore and the Cancer Registry in January 2016 where a team from the Cancer Registry started the first project on cervical cancer. If successful, they would potentially identify and screen high risk patients earlier and leave the low risk patients unburdened. 

Now there are two ongoing projects, one on cervical cancer and one on multitask learning for cancer. The goal is to make predictions more accurate and improve precision medicine. 

– If successful we can potentially identify and screen high risk earlier and leave the low risk unburdened. The individual and social impact of such a strategy is significant. This may be the reason why Joe Biden mentioned details from this project at a UN Assembly last year, Widerberg said.

Former Vice President Joe Biden led the American cancer initiative known as the Cancer Moonshot Blue Ribbon Panel. Two years ago, when the collaborative project between Norway and the USA had just started, the Blue Ribbon Panel released a report describing ten transformative research recommendations for achieving the Cancer Moonshot’s ambitious goal of making a decade’s worth of progress in cancer prevention, diagnosis, and treatment in just 5 years.

One of the ten recommendations was to expand use of proven cancer prevention and early detection strategies.

The major research questions
– One of the major research questions right now is How do we design the optimal screening programs? Another is how to actually take advantage of the registry data that we have, said Giske Ursin, Director of the Cancer Registry of Norway.

In Norway, and similarly in the other Nordic countries, we have registries on various diseases, pregnancy/births, vaccinations, work history/unemployment, income and much more. We have data sets dating from the 1950s. That is unique in the world. 

– If you look at enough data, you can find interesting links that can be explored in the clinical world or elsewhere. For instance; how do other diseases affect cancer diseases? We need international expertise to cover areas we are not experts on ourselves, she said, showing a picture of one of the super computers at Lawrence Livermore.

Cancer and national security
Lawrence Livermore National Laboratory is a national security laboratory and part of the U.S Department of Energy. The laboratory has over 5000 employees, of which at least half are engineers and researchers.

– We have the mandate from the government to push the forefront on subjects like bio security. Precision medicine is alined with the bio security mission, but it is even more relevant to the super computing research mandate. What are the next types of problems that will move this forward? Biomedical data complexity. That is why we are in this, Ana Paula de Oliveira Sales from Lawrence Livermore National Laboratory said in her presentation. 

Some ingredients of the project on cervical cancer is to improve cancer outcome prediction by combining disparate cancer types. The preliminary results are encouraging.

 

Break down barriers
John-Arne Røttingen, CEO of the Research Council of Norway, gave a talk on how collaborations between the Nordic countries and other countries are important for population based clinical research and health research.

– Personalized medicine is full of promise and we want to contribute to this progress, but we cannot do this only with our data. We have to collaborate with other countries and with different fields of research, he said.

One important country in that respect is of course the USA.

Kenneth J. Braithwaite, U.S Ambassador to Norway, talked about the opportunities with the Norwegian databases in a meeting in the Oslo Cancer Cluster innovation park 20 September 2018.

— I have learned the past few years that data is king, and we need to wrap our arms around this. I think there is a responsibility from the governments to begin to break down the barriers and truly find a cure to cancer. That’s what we are up against, said U.S. Ambassador to Norway Kenneth J. Braithwaite, who is Rear Admiral of United States Navy (Retired).

— As we say in the Navy, full speed ahead!

Funding Innovation in BioPharma and IT

What kind of work does it take to receive PERMIDES funding for innovative concepts and projects? Meet one of the companies that just received funding. 

 

22 collaboration projects will receive a total of 1,25 Million Euros from PERMIDES for innovation projects between small and medium sized enterprises (SMEs) from biopharma, bioinformatics and the IT sector. 

One of the lucky companies to receive innovation funding is Oslo Cancer Cluster member Myhere. For MyHere, it was especially important that the PERMIDES initiative is focused on the intersection between BioPharma and IT.

– Working with partners that are specialized in our field makes it easier to communicate the mission we are on, the concrete problems we are trying to solve and to qualify if we are a good match for each other or not. Furthermore, as we learned about the people and companies involved with PERMIDES, we discovered that we could learn a lot from the experiences of other SMEs in the program, says Jon-Bendik Thue, CEO at MyHere.

An innovative health app
MyHere’s mission is mainly carried out through the use of their app. This app, which pinpoints levels of Prostate Specific Antigen (PSA) in the bloodstream, enables a clearer outlook on potential prostate cancer and when to promptly, and timely, seek help. Thus, this app creates a balanced overview of prostate cancer that can save the patient and doctor from underdoing and overdoing the process. Essentially, the app is designed to save lives.

In this video, from MyHere’s webpage, the company explains the concept:

Essential health data
The funding will enable MyHere to start with a project that manages content from owners of health data. Health data is a tremendous resource, but unfortunately also tremendously underutilized. One important factor is the issue with getting consent from the owner of health data for research purposes. Typically, the owner is the individual the information was generated from, often in the role as a patient.

– As a provider of medical services directly to consumers, while at the same time organizing data across patient journeys, we are in a unique position to help solve the issue with consent for use of data. The funding from PERMIDES will allow us to build a dynamic data owner content management system, that will be integrated into our medical service platform. We are very excited about this project and we look forward to implementing it with our partner FramX, says Thue.

– Without this funding, we would have had to postpone the initiative without knowing when we would be able to realize it. Now we are thrilled that we will be able to hit the ground running right after the short Norwegian summer, he adds.

More winners in this round
Another Oslo Cancer Cluster member that got funding in this PERMIDES call is Arctic Pharma, a small start-up company committed to developing innovative anti-cancer drugs by exploiting the peculiar metabolic features of cancer cells.

These two Oslo Cancer Cluster members were among six Norwegian companies involved in four successful applications for Innovation Voucher funding. All of them will be able to initiate their joint projects in August and expect to see results early next year.